The increase in the number of hepatocellular carcinoma
patients in the United States being wait-listed for transplant is
leading to a greater incidence of wait-listing for all individuals with hepatitis C.
“The demand for liver transplantation for hepatocellular carcinoma is likely going to continue to rise and further strain our already limited donor pool,” Jennifer A. Flemming, MD, FRCP(C), MAS, of the University of California at San Francisco, said at The Liver Meeting.
“This could influence HCC listing policy over the next decade and may
push the transplant community to consider nontransplant alternatives
[for HCC patients].”
Researchers analyzed data from 20,325 adult patients listed for liver
transplantation secondary to HCV on the Scientific Registry for
Transplant Recipients database between 2003 and 2010. Patients were
considered to be wait-listed for end-stage liver disease (ESLD) if their
MELD score was 15 or greater at the initial wait-list date. Patients
were considered wait-listed for HCC if they were listed with HCC or
received a MELD exception for HCC within 180 days of entering the wait